Cenexel Iresearch LLC

1. Moderna TX, Inc. $7,517,061 1,241 payments
2. ITI, Inc. $5,737,478 1,366 payments
3. Teva Pharmaceuticals USA, Inc. $3,930,557 288 payments
4. Eli Lilly and Company $2,890,968 40 payments
5. AbbVie, Inc. $2,071,499 193 payments
6. Sumitomo Pharma America, Inc. $975,097 50 payments
7. Sanofi Pasteur Inc. $721,734 29 payments
8. Corium, Inc. $707,959 49 payments
9. Vanda Pharmaceuticals Inc. $630,109 28 payments
10. Boehringer Ingelheim Pharmaceuticals, Inc. $530,232 18 payments

1. Iti-007-451 $2,033,541 675 payments
2. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $1,860,482 112 payments
3. A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $1,329,308 21 payments
4. An Open-Label Multiple Oral Dose Study to Determine the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 10 to 17 Years, Diagnosed With Bipolar I Or II Disorder (Bipolar Depression) $1,281,613 47 payments
5. Iti-007-321 $1,054,890 370 payments
6. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $979,373 12 payments
7. A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia $906,158 57 payments
8. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $870,490 1 payment
9. A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older $812,659 18 payments
10. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $774,892 66 payments

1. Patient care $294,425 15 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.